ArticleAbdominal radiology (New York)2026
Does Gd-EOB-DTPA-enhanced T1 mapping have a role in the staging of fibrosis and inflammation in autoimmune hepatitis? A prospective study.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesAutoimmune hepatitis (AIH) is an immune-mediated liver disease that may progress to cirrhosis if untreated. Liver biopsy is the gold standard for assessing fibrosis and inflammation, but it is invasive and prone to sampling errors. This prospective study evaluated whether MRI T1 mapping with gadoxetic acid (Gd-EOB-DTPA) can noninvasively predict fibrosis stage and inflammatory activity in AIH. We compared several post-contrast T1 mapping-derived formulas to determine accuracy in detecting significant (F2-F4) and advanced (F3-F4) fibrosis and higher inflammatory activity (PPA 2-4). MATERIALS &
methodsOver three years, 33 AIH patients underwent a multiparametric liver MRI protocol with post-Gd-EOB-DTPA T1 mapping. Biopsies were performed up to three months prior. We measured standard pre- and post-contrast T1, adjusted liver T1 formulas, and hepatic uptake rates (Khep). Independent t-tests, Mann-Whitney U-tests, and ROC curves compared these indices against Metavir (F0-F4) and Desmet inflammatory grading (PPA 0-4).
resultsPost-contrast T1 at 20 min (AUC 0.822; 95% CI 0.674-0.970) and a mathematical formula (Adjusted T1 Liver B) (AUC 0.815; 95% CI 0.660-0.970) distinguished advanced (F3-F4) from non-advanced (F0-F2) fibrosis. However, none of the MRI-based parameters differentiated significant fibrosis (F2-F4) or higher inflammatory grades (PPA 2-4) from lower ones. Post-contrast T1 mapping did not outperform simpler pre-contrast T1 measurements (p > 0.05).
conclusionIn AIH, post-Gd-EOB-DTPA T1 mapping within a standard liver MRI protocol can identify advanced fibrosis, correlating well with the histopathological gold standard. However, it does not outperform simpler pre-contrast T1 measurements or reliably distinguish significant fibrosis or severe inflammation.
Indexed as
Identifiers
40689953What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.